BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, ...

BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement ...

BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...

Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is ...

Pfizer has agreed to reimburse BioNTech for $364.5 million of the claimed royalties paid to NIH and $170.0 million of the claimed royalties paid to the University of Pennsylvania. Write to Dean Seal ...

game se paise kaise kamaye Pfizer/BioNTech COVID-19 vaccine first granted emergency use authorization in the UK The Lancet reveals the secrets of anti-cancer missile ADC drugs: 5 marketed products and ...

BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...